The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Nov. 26, 1:08 AM

Slide #14. Lexicon Pharmaceuticals, Inc. Secondary Offering

Company: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Date announced: 11/19/2014
Shares Offered: 49,751,244
Secondary Offering Details: Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it commenced an offering to sell, subject to market and other conditions, $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to $7,500,000 of additional shares of common stock. All of the shares in the offering are to be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. will be acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated will be acting as co-managers for the offering.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development of treatments for human disease. Co. is engaged in the development of its two drug candidates, LX4211 for type 1 and type 2 diabetes and telotristat etiprate for carcinoid syndrome. Co.'s other clinical and preclinical development programs include LX1033 for the treatment of irritable bowel syndrome; LX2931 for the treatment of autoimmune disease; as well as LX7101, which is under evaluation as a potential treatment for glaucoma. Co. has developed small molecule compounds from a number of additional drug programs into various stages of preclinical development, including LX2761 for the treatment of diabetes.
Open the LXRX Page at The Online Investor »

Company Name:  Lexicon Pharmaceuticals, Inc.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding LXRX:  20
Total Market Value Held by ETFs:  $13.21M
Total Market Capitalization:  $489.00M
% of Market Cap. Held by ETFs:  2.70%
 

Open the LXRX Page at The Online Investor (in a new window) »

November 26, 2014    1:08 AM Eastern
Quotes delayed 20 minutes



Buy (3.17 out of 4)
53rd percentile
(ranked higher than approx. 53% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.